Differentiating Type 1, LADA, and Type 2 Diabetes

Initial Clinical Assessment

• The American Diabetes Association recommends combining clinical presentation features with islet autoantibody testing and C-peptide measurement to differentiate Type 1, LADA, and Type 2 diabetes, where autoantibody positivity distinguishes autoimmune diabetes from Type 2, and the rate of progression differentiates Type 1 from LADA 1
• Type 1 diabetes is characterized by younger age at diagnosis (<35 years), lower BMI (<25 kg/m²), unintentional weight loss, ketoacidosis, and high blood sugar levels at presentation 2, 3
• Hallmark symptoms of Type 1 diabetes include polyuria/polydipsia with approximately 50% presenting with diabetic ketoacidosis 2, 3
• Rapid progression to absolute insulin dependence (weeks to months) is typical of Type 1 diabetes 1
• LADA presents with adult onset typically after age 30-35 years, with a phenotype initially resembling Type 2 diabetes but with lower BMI, fewer metabolic risk factors, and better lipid profiles 4
• Clinical features suggestive of autoimmune diabetes in LADA include younger age, unintentional weight loss, lean body habitus, or rapid progression to insulin requirement 4
• Slower progression to insulin dependence (typically over a few years rather than weeks to months) is characteristic of LADA 4
• Type 2 diabetes features include higher BMI (typically >25 kg/m²), older age, gradual onset without acute symptoms, and presence of metabolic syndrome features (hypertension, dyslipidemia, central obesity) 5, 2
• Insulin resistance with relative insulin deficiency is typical of Type 2 diabetes 6, 5

Diagnostic Laboratory Testing Algorithm

• The American Diabetes Association recommends ordering autoantibody testing in adults with suspected autoimmune diabetes based on clinical features 4
• Glutamic acid decarboxylase antibodies (GADA) are most sensitive for LADA 4
• Presence of islet autoantibodies distinguishes autoimmune diabetes (Type 1/LADA) from Type 2 diabetes 4
• Measure C-peptide to assess beta-cell function, with Type 1 diabetes indicating severe beta-cell deficiency (C-peptide <200 pmol/L) 1
• LADA is characterized by C-peptide levels in the range of 200-600 pmol/L or low-normal range 4
• Type 2 diabetes is indicated by C-peptide levels >600 pmol/L or elevated 1

Diagnostic Decision Framework

• Multiple autoantibodies + acute presentation + age <35 years + low C-peptide (<200 pmol/L) = Type 1 Diabetes 1
• Single or multiple autoantibodies + gradual onset + age >30-35 years + intermediate C-peptide (200-600 pmol/L) + initial response to oral agents = LADA 4
• Age >35 years + BMI >25 kg/m² + metabolic syndrome features + elevated C-peptide (>600 pmol/L) = Type 2 Diabetes 5, 1

Staging for Autoimmune Diabetes

• Once autoimmune diabetes is confirmed, use the three-stage classification: Stage 1 (multiple autoantibodies + normoglycemia + presymptomatic), Stage 2 (autoantibodies + dysglycemia + presymptomatic), and Stage 3 (autoantibodies + overt diabetes + symptomatic) 7, 8
• This staging applies to both Type 1 and LADA, with LADA progressing more slowly through these stages 4